Loading...
•
Sep 28
Revvity Q3 2025 Earnings Report
Revvity reported Q3 2025 results with modest revenue growth, lower profitability, and reaffirmed guidance.
Key Takeaways
Revvity posted $699 million in revenue for Q3 2025 with slight organic growth and GAAP EPS of $0.40. Despite declines in operating and net income, the company reaffirmed full-year organic growth guidance and raised adjusted EPS outlook.
Revenue reached $699 million, showing slight organic growth of 1%
GAAP EPS fell to $0.40 from $0.77 in the prior year
Adjusted EPS came in at $1.18, down from $1.28 last year
Revvity authorized a new $1 billion share repurchase program
Revvity
Revvity
Revvity Revenue by Segment
Revenue by Segment
Life Sciences Revenue
CapyFin.comDiagnostics Revenue
CapyFin.com Forward Guidance
Revvity reaffirmed its full-year organic growth guidance of 2%–4% and raised its adjusted EPS outlook to $4.90–$5.00.
Positive Outlook
- Full-year organic growth guidance reaffirmed at 2%–4%
- Adjusted EPS guidance raised to $4.90–$5.00
- Continued execution of innovation and strategic partnerships
- Strong adjusted operating margins across segments
- Resilient demand across Diagnostics and Life Sciences segments
Challenges Ahead
- GAAP operating margin declined from prior year
- Adjusted EPS decreased year-over-year
- GAAP EPS dropped to nearly half of prior year’s figure
- Net income declined significantly year-over-year
- Lower adjusted operating income in both business segments
Revenue & Expenses
Visualization of income flow from segment revenue to net income